Adam Brickman at Columbia University, New York City, cautioned that the ARIA profile might be worse in clinical practice, where a broader range of patients are likely to be treated and monitoring may be less stringent. Brickman believes the trials’ lack of diversity leaves unclear how the results would generalize to a typical clinic population.

Others have expressed similar concerns, with one recent study noting that 92 percent of Medicare patients would not have qualified for the Phase 3 trials due to comorbidities such as cerebrovascular disease and other exclusions (Oct 2021 news). Additional reports of adverse events and a death potentially linked to aducanumab have surfaced (Nov 2021 conference news).

Read more: https://www.alzforum.org/news/research-news/aduhelm-phase-3-data-shows-aria-common-sometimes-serious